$1.24
3.33%
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US0144421072
Symbol
ALEC

Alector, Inc. Stock price

$1.24
-1.75 58.53% 1M
+0.17 15.89% 6M
-0.65 34.39% YTD
-3.67 74.75% 1Y
-7.33 85.53% 3Y
-11.49 90.26% 5Y
-15.39 92.54% 10Y
-15.39 92.54% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+0.04 3.33%
ISIN
US0144421072
Symbol
ALEC
Industry

Key metrics

Basic
Market capitalization
$135.4m
Enterprise Value
$-146.2m
Net debt
positive
Cash
$291.1m
Shares outstanding
107.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.0 | 8.1
EV/Sales
negative | negative
EV/FCF
0.7
P/B
2.4
Financial Health
Equity Ratio
27.1%
Return on Equity
-93.9%
ROCE
-48.4%
ROIC
2,510.0%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$69.1m | $16.7m
EBITDA
$-117.1m | $-173.3m
EBIT
$-123.7m | $-174.2m
Net Income
$-107.7m | $-169.5m
Free Cash Flow
$-197.6m
Growth (TTM | estimate)
Revenue
12.3% | -83.4%
EBITDA
33.0% | -24.2%
EBIT
32.4% | -20.2%
Net Income
32.0% | -42.4%
Free Cash Flow
11.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-169.5% | -1,039.9%
EBIT
-179.1%
Net
-156.0% | -1,016.9%
Free Cash Flow
-286.2%
More
EPS
$-1.1
FCF per Share
$-1.8
Short interest
5.3%
Employees
238
Rev per Employee
$420.0k
Show more

Is Alector, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Alector, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Alector, Inc. forecast:

1x Buy
7%
8x Hold
57%
5x Sell
36%

Analyst Opinions

14 Analysts have issued a Alector, Inc. forecast:

Buy
7%
Hold
57%
Sell
36%

Financial data from Alector, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
69 69
12% 12%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
3% 3%
81%
- Research and Development Expense 137 137
27% 27%
198%
-117 -117
33% 33%
-170%
- Depreciation and Amortization 6.63 6.63
19% 19%
10%
EBIT (Operating Income) EBIT -124 -124
32% 32%
-179%
Net Profit -108 -108
32% 32%
-156%

In millions USD.

Don't miss a Thing! We will send you all news about Alector, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alector, Inc. Stock News

Neutral
GlobeNewsWire
11 days ago
Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson's disease; both advancing toward IND-enabling studies
Neutral
GlobeNewsWire
27 days ago
Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint
Negative
Reuters
27 days ago
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
More Alector, Inc. News

Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Head office United States
CEO Arnon Rosenthal
Employees 238
Founded 2013
Website alector.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today